▲ 0.95%
prev close
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Congressional Trades
2
All tracked trades
Members Trading
2
Unique members
Net Activity
-2
0 buys · 2 sells
Members Who Traded This Stock
2 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-03-03 | ALCAlcon Inc. Ordinary Shares | Sell | $1,001 - $15,000 | 464d ago | — | |
| 2023-07-10 | ALCAlcon Inc. Ordinary Shares | Sell | $15,001 - $50,000 | 1074d ago | — |
2025-03-03
Julie Johnson
ALC
Amount
$1,001 - $15,000
Filed
464d ago
2023-07-10
Daniel Goldman
ALC
Amount
$15,001 - $50,000
Filed
1074d ago
Recent News
Powered by Polygon.io
Ophthalmology Devices Market Report Released, Includes Profiles of EssilorLuxottica, Alcon, Bausch + Lomb, and 20 Others
Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?
National Advertising Division Finds Certain ACUVUE® Oasys Max Claim Supported; Recommends Modification or Discontinuation of Others
LENSAR Stock Plunges—Alcon Scraps Merger After Prolonged Regulatory Review
2026 DallasCISO ORBIE Awards Recognize Top Security Executives
Trade Timeline
Congressional activity, newest first
Julie Johnson
2025-03-03 · Sale
$1,001 - $15,000
Daniel Goldman
2023-07-10 · Sale
$15,001 - $50,000